Percutaneous coronary intervention vs. optimal medical therapy - The other side of the coin: Medication adherence

Journal of Clinical Pharmacy and Therapeutics

Volumn 38, Issue 6, 2013, Pages 476-479

  Kocas, C ^a   Abaci, O ^a   Oktay, V ^a   Coskun, U ^a   Bostan, C ^a   Yildiz, A ^a   Ozkan, A Arat ^a   Gurmen, T ^a   Ersanli, M ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

coronary artery disease; medication adherence; optimal medical therapy; percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRESCRIPTION; PROPHYLAXIS; REIMBURSEMENT; SURVIVOR;

CORONARY ARTERY DISEASE; MEDICATION ADHERENCE; OPTIMAL MEDICAL THERAPY; PERCUTANEOUS CORONARY INTERVENTION;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY ARTERY DISEASE; ENDPOINT DETERMINATION; EVIDENCE-BASED MEDICINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84886946510     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12091     Document Type: Article

References (27)

1. Smith SC Jr, Benjamin EJ, Bonow RO, et al,. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. J Am Coll Cardiol, 2011; 58: 2432-2446.
2. Boden WE, O'Rourke RA, Teo KK, et al,. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med, 2007; 356: 1503-1516.
3. Maron DJ, Boden WE, Weintraub WS, Calfas KJ, O'Rourke RA,. Is optimal medical therapy as used in the COURAGE trial feasible for widespread use? Curr Treat Options Cardiovasc Med, 2011; 13: 16-25.
4. Maron DJ, Boden WE, O'Rourke RA, et al,. Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug evaluation) trial. J Am Coll Cardiol, 2010; 55: 1348-1358.
5. O'Gara PT,. The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial: can we deliver on its promise? J Am Coll Cardiol, 2010; 56: 1359-1361.
6. Kereiakes DJ, Teirstein PS, Sarembock IJ, et al,. The truth and consequences of the COURAGE trial. J Am Coll Cardiol, 2007; 50: 1598-1603.
7. Baroletti S, Dell'Orfano H,. Medication adherence in cardiovascular disease. Circulation, 2010; 121: 1455-1458.
8. Newby LK, LaPointe NM, Chen AY, et al,. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation, 2006; 113: 203-212.
9. Jackevicius CA, Li P, Tu JV,. Prevalence, predictors and outcomes of primary non-adherence after acute myocardial infarction. Circulation, 2008; 117: 1028-1036.
10. Jackevicius CA, Mamdani M, Tu JV,. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA, 2002; 288: 462-467.
11. Ho PM, Bryson CL, Rumsfeld JS,. Medication adherence: its importance in cardiovascular outcomes. Circulation, 2009; 119: 3028-3035.
12. Borden WB, Redberg RF, Mushlin AI, Dai D, Kaltenbach LA, Spertus JA,. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. JAMA, 2011; 305: 1882-1889.
13. Ho PM, Magid DJ, Shetterly SM, et al,. Medication adherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J, 2008; 155: 772-779.
14. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS,. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care, 2005; 43: 521-530.
15. Hannan EL, Samadashvili Z, Cozzens K, et al,. Comparative outcomes for patients who do and do not undergo percutaneous coronary intervention for stable coronary artery disease in New York. Circulation, 2012; 125: 1870-1879.
16. Fox K, Garcia MA, Ardissino D, et al,. Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG). Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J, 2006; 27: 1341-1381.
17. Gibbons RJ, Abrams J, Chatterjee K, et al,. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol, 2007; 50: 2264-2274.
18. Spertus JA, Kettelkamp R, Vance C, et al,. Prevalence, predictors and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation, 2006; 113: 2803-2809.
19. Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, Schwartz JS, Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med, 2005; 165: 1147-1152.
20. Lau DT, Nau DP,. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care, 2004; 27: 2149-2153.
21. Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM,. Adherence to statin treatment and readmission of patients after myocardial infarction: a 6 years follow up study. Heart, 2002; 88: 229-233.
22. Wei L, Flynn R, Murray GD, MacDonald TM,. Use and adherence to beta-blockers for secondary prevention of myocardial infarction: who is not getting the treatment? Pharmacoepidemiol Drug Saf, 2004; 13: 761-766.
23. Osterberg L, Blaschke T,. Adherence to medication. N Engl J Med, 2005; 353: 487-497.
24. Rasmussen JN, Chong A, Alter DA,. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after myocardial infarction. JAMA, 2007; 297: 177-186.
25. Iakovou I, Schmidt T, Bonizzoni E, et al,. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA, 2005; 293: 2126-2130.
26. Rinfret S, Rodés-Cabau J, Bagur R, et al,. Telephone contact to improve adherence to dual antiplatelet therapy after drug-eluting stent implantation. Heart, 2013; 99: 562-569.
27. Kulik A, Shrank WH, Levin R, Choudhry NK,. Adherence to statin therapy in elderly patients after hospitalization for coronary revascularization. Am J Cardiol, 2011; 107: 1409-1414.